期刊
BLOOD ADVANCES
卷 1, 期 1, 页码 21-30出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/bloodadvances.2016000216
关键词
-
类别
资金
- Mayo Clinic Harvey-Yulman Charitable Foundation for Myelofibrosis Tissue Bank
- Clinical Database of Molecular and Biological Abnormalities, The Henry J. Predolin Foundation for Research in Leukemia, Mayo Clinic, Rochester, MN
- Associazione Italiana per la Ricerca sulCancro (AIRC) [1005]
- Bando Ministero della Salute Giovani Ricercatori-Ricerca Finalizzata [GR-2011-02352109]
- AIRC [IG-15967]
- Amici di Beat Leukemia Onlus
Polycythemia vera (PV) is characterized by JAK2 and essential thrombocythemia (ET) by JAK2, calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; we describe the occurrence and prognostic relevance of DNA sequence variants/mutations other than JAK2/CALR/MPL. A myeloid neoplasm-relevant 27-gene panel was used for next-generation sequencing of bone marrow or whole blood DNA and conventional tools were used for analysis. Adverse variants/mutations were identified by age-adjusted multivariable analysis of impact on overall, leukemia-free, or myelofibrosis-free survival. Fifty-three percent of 133 Mayo Clinic patients with PV and 53% of 183 with ET harbored 1 or more sequence variants/mutations other than JAK2/CALR/MPL; the most frequent were TET2 and ASXL1. Adverse variants/mutations in PV included ASXL1, SRSF2, and IDH2 and in ET SH2B3, SF3B1, U2AF1, TP53, IDH2, and EZH2; combined prevalence was 15% and 15%, respectively. Adverse variants/mutations were associated with inferior survival in both PV (median, 7.7 vs 16.9 years) and ET (median, 9 vs 22 years) and the effect was independent of conventional prognostic models with respective hazard ratio (95% confidence interval) of 2.8 (1.5-5.1) and 2.6 (1.4-4.8); these observations were validated in 215 Italian patients with PV and 174 with ET. In both Mayo Clinic and Italian cohorts, leukemic or fibrotic progression was also predicted by adverse variants/mutations. Number of mutations did not provide additional prognostic information. We conclude that targeted deep sequencing in PV and ET allows for genetic risk stratification that is independent of clinically derived prognostic models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据